NACO First-Line ART Pathway Evidence-based HIV Treatment Initiation · v2.0
← HIV Clinical Hub
⚙ Test and Treat: Rapid ART initiation is recommended for all PLHIV, preferably within 7 days, barring specific OIs requiring stabilisation first.
1. Patient Demographics & Vitals
2. Clinical & Laboratory Parameters
3. Disease Staging
⚙ Illness Scripts: Acute Retroviral Syndrome

Acute HIV infection often presents as a mononucleosis-like illness 2 to 4 weeks post-exposure. The clinical triad of fever, pharyngitis, and rash with mucocutaneous ulcers should raise suspicion.

Acute HIVEBV MonoSecondary Syphilis
Fever, non-exudative pharyngitis, generalised tender lymphadenopathy Exudative pharyngitis, profound fatigue, atypical lymphocytes Maculopapular rash (palms/soles), condylomata lata
Maculopapular rash (trunk/face); mucocutaneous ulcers (highly specific) Hepatosplenomegaly; rash after Ampicillin Painless lymphadenopathy; history of painless chancre
High HIV RNA VL; antibody tests may be negative (window period) Positive Monospot; EBV VCA IgM positive Positive VDRL/RPR and TPHA
Clinical Pearls & Caveats
⚠ IRIS: Starting ART with undiagnosed OIs can trigger paradoxical worsening. Delay ART: 4 to 6 weeks for Cryptococcal Meningitis; 2 to 8 weeks for TB Meningitis. Do NOT delay for pulmonary TB.
Rifampicin-DTG Interaction: Rifampicin lowers DTG trough levels by ~54%. Must add DTG 50mg BD (extra dose 12 hours after TLd). Continue for 2 weeks post-Rifampicin.
ABC Hypersensitivity: Multi-organ reaction linked to HLA-B*5701. Fever, rash, GI symptoms, respiratory distress within first 6 weeks. Stop immediately; never rechallenge (risk of fatal anaphylaxis).
DTG and Weight Gain: Associated with excess weight gain, particularly in women and patients of African descent. Monitor fasting glucose and lipid profile.
Abbreviations: ART · TDF · TAF · 3TC · DTG · AZT · ABC · CrCl · IRIS · AHD · OI · CrAg · PLHIV (People Living with HIV) · VL (Viral Load)
Algorithm References
  1. NACO. National Guidelines for HIV Care and Treatment. MoHFW, GoI; 2021.
  2. WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. 2021.
  3. Venter WDF et al. N Engl J Med. 2019;381(9):803-815.
  4. NACO. National Technical Guidelines on ART. 2018 (Updated 2021).
How to Cite This Tool

AMA: Umakanth S. NACO First-Line ART Pathway. MEDiscuss. Published 2026. Accessed .

Vancouver: Umakanth S. NACO First-Line ART Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

⚠ Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was designed and developed by
Dr. Shashikiran Umakanth using the available evidence base. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Therapeutic Pathways & Algorithms
Specialties Internal Medicine, Infectious Diseases, HIV Medicine
Related Clinical Tools
HIV Clinical Pathway HubNACO Second-Line ART PathwayNACO PMTCT Pathway
Back to All Medical Calculators & Pathways